" class="no-js "lang="en-US"> Matinas BioPharma Announces MAT2203 Will Feature at ECCMID
Friday, June 09, 2023

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Matinas BioPharma, a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology to maximize global clinical impact and patient access, announces that MAT2203, an oral LNC formulation of amphotericin B (AMB), will be featured in two oral presentations at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The hybrid in-person and virtual Congress is being held April 15-18 in Copenhagen and the MAT2203 presentations will both take place on April 18.

The two presentations are as follows:

  • “All-oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a phase II randomized trial” will be presented by David Boulware, MD, MPH, Professor of Medicine at the University of Minnesota and Principal Investigator for the Phase 2 EnACT trial evaluating MAT2203 in cryptococcal meningitis.
  • “Calcaneal Rhodotorula mucilaginosa osteomyelitis treated with oral amphotericin B (MAT2203)” – Senior Author, Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.

“We are delighted that clinical evidence supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections will be presented at this prestigious conference (ECCMID),” said Theresa Matkovits, PhD, Chief Development Officer of Matinas BioPharma. “The efficacy of amphotericin B is well established, but this fungicidal drug is typically administered selectively only to patients with severe disease because of its toxicity, which significantly limits its use. MAT2203 reduces systemic toxicity by directing amphotericin B to targeted cells at sites of infection, supporting a favorable safety profile relative to IV-administered AMB with the additional benefit of oral administration. The data to be presented at ECCMID, from both our EnACT Phase 2 trial and a compelling compassionate use case, support our strategy of developing the ideal antifungal agent for the treatment of a variety of invasive fungal infections while also potentially having a dramatic pharmacoeconomic impact on the cost of treating these deadly diseases.”

“Importantly, success with MAT2203 gives us confidence that our platform technology can be applied beyond small molecules to a multitude of treatment modalities that alter the genetic mechanisms that underlie disease, an area we view as the future of medicine,” added Dr. Matkovits. “We believe that our delivery platform holds promise for the targeted delivery of gene therapy, providing Matinas with the opportunity to develop robust internal and partnered drug development candidates.”

  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more